194 related articles for article (PubMed ID: 15260385)
1. Diabetes could cost you your kidneys, act now!
Viswanathan V
J Assoc Physicians India; 2003 Nov; 51():1043-4. PubMed ID: 15260385
[No Abstract] [Full Text] [Related]
2. Hypertension arm of ADVANCE defines extent of renal protection using perindopril/indapamide in type 2 diabetics.
Cardiovasc J Afr; 2008; 19(4):226. PubMed ID: 18776973
[No Abstract] [Full Text] [Related]
3. [Diabetic nephropathy].
Morcos M; Zeier M; Schwenger V
Dtsch Med Wochenschr; 2007 May; 132(19):1039-42. PubMed ID: 17476634
[No Abstract] [Full Text] [Related]
4. Prevention of end-stage renal disease due to type 2 diabetes.
Hostetter TH
N Engl J Med; 2001 Sep; 345(12):910-2. PubMed ID: 11565525
[No Abstract] [Full Text] [Related]
5. [Losartan and the kidney protection. The RENAAL study].
Recenti Prog Med; 2001 Dec; 92(12):788. PubMed ID: 11822103
[No Abstract] [Full Text] [Related]
6. [The kidneys and diabetes].
Rüster C; Sämann A; Wolf G
Dtsch Med Wochenschr; 2008 Sep; 133(37):1848-52. PubMed ID: 18770486
[No Abstract] [Full Text] [Related]
7. Antihypertensive therapy in patients with type 2 diabetes mellitus: focus on nephropathy.
Mann JF; Thomae U; Gerstein HC; Franke J; Lièvre M
Adv Nephrol Necker Hosp; 1999; 29():241-55. PubMed ID: 10561748
[No Abstract] [Full Text] [Related]
8. Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.
Cardiovasc J S Afr; 2001; 12(4):242-3. PubMed ID: 11766619
[No Abstract] [Full Text] [Related]
9. The treatment of hypertension in patients with diabetes mellitus.
de Nobel E
Neth J Med; 1989 Dec; 35(5-6):219-24. PubMed ID: 2699651
[No Abstract] [Full Text] [Related]
10. [Obesity in the service of Justice. New drug-combination leads to protection of the kidney].
Streier K
Fortschr Med; 1997 Nov; 115(32):54-5. PubMed ID: 9480271
[No Abstract] [Full Text] [Related]
11. [Hypertension therapy for type 2 diabetics].
Bönner G
MMW Fortschr Med; 2007 Jun; 149(23):45, 47-8. PubMed ID: 18062579
[No Abstract] [Full Text] [Related]
12. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
13. Diabetes mellitus. A significant risk.
Barnett A
Nurs Times; 1994 Jan 12-18; 90(2):60-4. PubMed ID: 8302651
[No Abstract] [Full Text] [Related]
14. [Strategies in prevention, development and progression of diabetic nephropathy].
Luño J
Nefrologia; 2005; 25 Suppl 4():48-56. PubMed ID: 16392324
[No Abstract] [Full Text] [Related]
15. [Therapy for hypertension associated with diabetes mellitus].
Kushiro T; Kanmatsuse K
Nihon Naika Gakkai Zasshi; 2003 Feb; 92(2):243-9. PubMed ID: 12652728
[No Abstract] [Full Text] [Related]
16. [Evidence based treatment of diabetic nephropathy].
Sugimoto T
Nihon Rinsho; 2002 Oct; 60 Suppl 10():294-300. PubMed ID: 12430244
[No Abstract] [Full Text] [Related]
17. [Ambitious American guidelines for control of risk factors in diabetes. Was the aim put too high?].
Nilsson P; Attvall S; Weiss L
Lakartidningen; 2003 Jan; 100(1-2):26-30. PubMed ID: 12572133
[No Abstract] [Full Text] [Related]
18. Association between smoking and micro-albuminuria in hypertensive patients with type 2 diabetes mellitus.
Corradi L; Zoppi A; Tettamanti F; Malamani G; Lazzari P; Fogari R
J Hypertens Suppl; 1993 Dec; 11(5):S190-1. PubMed ID: 8158337
[No Abstract] [Full Text] [Related]
19. Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring.
Rossing K
Dan Med Bull; 2007 May; 54(2):79-98. PubMed ID: 17521525
[No Abstract] [Full Text] [Related]
20. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
